7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Jaw Diseases D007571 4 associated lipids
Jaw, Edentulous D007575 1 associated lipids
Jaw, Edentulous, Partially D007576 1 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Labyrinthitis D007762 2 associated lipids
Legg-Calve-Perthes Disease D007873 1 associated lipids
Leukemia D007938 74 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Chuang FH et al. Long-term sequential receptor activator of NF-κB ligand (RANKL) and osteoprotegrin (OPG) expression in lipopolysaccharide-induced rat periapical lesions. 2012 J. Oral Pathol. Med. pmid:21793936
Vik A et al. Serum osteoprotegerin and future risk of venous thromboembolism. The Tromsø study. 2012 Thromb. Res. pmid:22909822
Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. 2011 Nov-Dec Clin. Exp. Rheumatol. pmid:22032557
Arikan F et al. C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. 2011 Mar-Apr Int J Oral Maxillofac Implants pmid:21483881
Crespi R et al. Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. 2011 Jul-Aug Int J Oral Maxillofac Implants pmid:21841997
Franke S et al. Advanced glycation end products affect growth and function of osteoblasts. 2011 Jul-Aug Clin. Exp. Rheumatol. pmid:21906430
Rezg R et al. Inhibitors of vascular calcification as potential therapeutic targets. 2011 Jul-Aug J. Nephrol. pmid:21688249
Reyes-García R et al. [Cardiovascular disease and bone metabolism]. 2011 Aug-Sep Endocrinol Nutr pmid:21775224
Zhang M et al. EP1(-/-) mice have enhanced osteoblast differentiation and accelerated fracture repair. 2011 J. Bone Miner. Res. pmid:20939055
Gurban CV and Mederle O The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis. 2011 Rom J Morphol Embryol pmid:22119834
Millard SM et al. Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation. 2011 J. Bone Miner. Res. pmid:20939063
Tanaka H et al. Expression of RANKL/OPG during bone remodeling in vivo. 2011 Biochem. Biophys. Res. Commun. pmid:21771583
Meulman T et al. Impact of Porphyromonas gingivalis inoculation on ligature-induced alveolar bone loss. A pilot study in rats. 2011 J. Periodont. Res. pmid:21726226
Reinhard H et al. Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria. 2011 Cardiovasc Diabetol pmid:21801376
Gordon IK and Camphausen K Research highlights. 2011 Biomark Med pmid:21861664
Sood SK et al. Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. 2011 World J Surg pmid:21748518
Stein SH and Tipton DA Vitamin D and its impact on oral health--an update. 2011 J Tenn Dent Assoc pmid:21748977
Xie H et al. Omentin-1 attenuates arterial calcification and bone loss in osteoprotegerin-deficient mice by inhibition of RANKL expression. 2011 Cardiovasc. Res. pmid:21750093
Wang Y et al. Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. 2011 J Orthop Surg Res pmid:21752290
Jabbar S et al. Plasma vitamin D and cytokines in periodontal disease and postmenopausal osteoporosis. 2011 J. Periodont. Res. pmid:20731767
Lossdörfer S et al. PTH(1-34)-induced changes in RANKL and OPG expression by human PDL cells modify osteoclast biology in a co-culture model with RAW 264.7 cells. 2011 Clin Oral Investig pmid:20697756
Tipton DA et al. Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6. 2011 J. Periodont. Res. pmid:20701670
McGrath EE OPG/RANKL/RANK pathway as a therapeutic target in cancer. 2011 J Thorac Oncol pmid:21849854
Findlay DM and Atkins GJ Relationship between serum RANKL and RANKL in bone. 2011 Osteoporos Int pmid:21850548
Harada S and Takahashi N [Control of bone resorption by RANKL-RANK system]. 2011 Clin Calcium pmid:21814016
Nakamura M and Udagawa N [Osteoporosis and RANKL signal]. 2011 Clin Calcium pmid:21814019
Persson E and Lerner UH The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. 2011 J. Cell. Biochem. pmid:21815197
Üstündağ M et al. The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. 2011 J. Int. Med. Res. pmid:21819709
Bellido M et al. Improving subchondral bone integrity reduces progression of cartilage damage in experimental osteoarthritis preceded by osteoporosis. 2011 Osteoarthr. Cartil. pmid:21820069
Christoforidis A et al. Comparative study of dual energy X-ray absorptiometry and quantitative ultrasonography with the use of biochemical markers of bone turnover in boys with haemophilia. 2011 Haemophilia pmid:20825502
Lawrie A et al. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. 2011 Am. J. Pathol. pmid:21835155
Sudrová M et al. Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women. 2011 Clin. Appl. Thromb. Hemost. pmid:20682598
Mamalis AA et al. Chemical modification of an implant surface increases osteogenesis and simultaneously reduces osteoclastogenesis: an in vitro study. 2011 Clin Oral Implants Res pmid:21070383
Vitoratos N et al. Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. 2011 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:21074311
Belibasakis GN et al. Oral biofilm challenge regulates the RANKL-OPG system in periodontal ligament and dental pulp cells. 2011 Microb. Pathog. pmid:21075196
Peng S et al. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin. 2011 Bone pmid:21925296
Fan R et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: possible association with inflammatory cells. 2011 Chin. Med. J. pmid:21933620
Osorio A et al. Mineral-bone metabolism markers in young hemodialysis patients. 2011 Clin. Biochem. pmid:21933667
Nybo M et al. Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients. 2011 Basic Clin. Pharmacol. Toxicol. pmid:21726411
Fradet A et al. Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. 2011 Cancer Res. pmid:21734015
Campbell GM et al. Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. 2011 Osteoporos Int pmid:20480144
Kaneko K and Kawai S [Mechanisms and therapeutics of glucocorticoid-induced osteoporosis]. 2011 Nihon Rinsho Meneki Gakkai Kaishi pmid:21720102
Ueland T et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. 2011 J. Intern. Med. pmid:21623962
Wheater G et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. 2011 Osteoporos Int pmid:21625887
Karadag-Saygi E et al. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis. 2011 Gynecol. Endocrinol. pmid:21627558
Taylor R et al. Osteoclast formation and function in pigmented villonodular synovitis. 2011 J. Pathol. pmid:21706481
Zhang Y et al. Study of the mechanisms by which Sambucus williamsii HANCE extract exert protective effects against ovariectomy-induced osteoporosis in vivo. 2011 Osteoporos Int pmid:20414641
Conaway HH et al. Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor. 2011 J. Biol. Chem. pmid:21715325
El-Shehaby A et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. 2011 J. Clin. Immunol. pmid:21691937
Nich C et al. Oestrogen deficiency modulates particle-induced osteolysis. 2011 Arthritis Res. Ther. pmid:21696618
Clézardin P [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications]. 2011 Bull Cancer pmid:21700551
Celczyńska Bajew L et al. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. 2011 Kardiol Pol pmid:21678294
Dzida G [Decalcified bones, calcified heart?]. 2011 Kardiol Pol pmid:21678295
Roshandel D et al. Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. 2011 Calcif. Tissue Int. pmid:21964949
Davenport C et al. Identifying coronary artery disease in men with type 2 diabetes: osteoprotegerin, pulse wave velocity, and other biomarkers of cardiovascular risk. 2011 J. Hypertens. pmid:21970938
Miyamoto K et al. Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization. 2011 J. Exp. Med. pmid:22006978
Quemerais-Durieu MA et al. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)]. 2011 Ann. Endocrinol. (Paris) pmid:22008272
Koo HM et al. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients. 2011 Atherosclerosis pmid:22015178
Cianciolo G et al. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 2011 Nephrol. Dial. Transplant. pmid:20659908
Di Bartolo BA et al. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. 2011 Cardiovasc. Res. pmid:21447702
Ho TY et al. Effects of relaxin and estrogens on bone remodeling markers, receptor activator of NF-kB ligand (RANKL) and osteoprotegerin (OPG), in rat adjuvant-induced arthritis. 2011 Bone pmid:21419242
Chasseraud M et al. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification. 2011 Ther Apher Dial pmid:21426505
Duheron V et al. Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21402940
Dimitrow PP et al. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. 2011 J. Heart Valve Dis. pmid:21404893
Marques EA et al. Effects of resistance and aerobic exercise on physical function, bone mineral density, OPG and RANKL in older women. 2011 Exp. Gerontol. pmid:21316442
Chin A et al. Effects of medicinal herb salvia miltiorrhiza on osteoblastic cells in vitro. 2011 J. Orthop. Res. pmid:21319217
Mencej-Bedrač S et al. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women. 2011 Maturitas pmid:21411255
Lee JC et al. Role of RANK-RANKL-OPG axis in cranial suture homeostasis. 2011 J Craniofac Surg pmid:21415639
Mainini G et al. Serum osteoprotegerin correlates with age and bone mass in postmenopausal, but not in fertile age women. 2011 Clin Exp Obstet Gynecol pmid:22268274
Riksen EA et al. Human osteoblastic cells discriminate between 20-kDa amelogenin isoforms. 2011 Eur. J. Oral Sci. pmid:22243268
Yang Z et al. [Effects of negative pressure on osteogenesis in human bone marrow-derived stroma cells cultured in vitro]. 2011 Zhongguo Gu Shang pmid:22276514
Aydin H et al. Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats. 2011 Minerva Endocrinol. pmid:21519319
Altinova AE et al. Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. 2011 Scand. J. Clin. Lab. Invest. pmid:21486111
Mercatali L et al. Bone metastases detection by circulating biomarkers: OPG and RANK-L. 2011 Int. J. Oncol. pmid:21491082
Stein SH et al. Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts. 2011 J. Periodont. Res. pmid:21463327
Liang QQ et al. The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice. 2011 Bone pmid:21466864
Honda K Interleukin-6 and soluble interleukin-6 receptor suppress osteoclastic differentiation by inducing PGE(2) production in chondrocytes. 2011 J Oral Sci pmid:21467819
Moldenhauer A et al. Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. 2011 Eur. J. Immunol. pmid:21469100
Kim H et al. Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women. 2011 Menopause pmid:21471826
Mulcahy LE et al. RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells. 2011 Bone pmid:20854946
Aspenberg P et al. Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening. 2011 Bone pmid:20858557
Dimitri P et al. Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. 2011 Bone pmid:20932948
Yu H et al. Overexpression of osteoprotegerin promotes preosteoblast differentiation to mature osteoblasts. 2011 Angle Orthod pmid:20936961
Palaniswamy C et al. Association of warfarin use with valvular and vascular calcification: a review. 2011 Clin Cardiol pmid:21298649
Bostanci N et al. Effect of periodontal treatment on receptor activator of NF-κB ligand and osteoprotegerin levels and relative ratio in gingival crevicular fluid. 2011 J. Clin. Periodontol. pmid:21261673
Andersen GØ et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. 2011 Heart pmid:21270073
Tsukamoto S et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. 2011 Clin. Cancer Res. pmid:21270110
Bai P et al. Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. 2011 Respir. Res. pmid:22176920
Piedra M et al. "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". 2011 BMC Med. Genet. pmid:22185226
Sun Z and Tee BC Molecular variations related to the regional differences in periosteal growth at the mandibular ramus. 2011 Anat Rec (Hoboken) pmid:21157918
Cannon JG et al. Follicle-stimulating hormone promotes RANK expression on human monocytes. 2011 Cytokine pmid:21159522
Choe JY et al. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin. 2011 J. Rheumatol. pmid:21159831
Mahoney DJ et al. TSG-6 inhibits osteoclast activity via an autocrine mechanism and is functionally synergistic with osteoprotegerin. 2011 Arthritis Rheum. pmid:21162099
Nahidi L et al. Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. 2011 Inflamm. Bowel Dis. pmid:20848544
Čolović M et al. FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. 2011 Int. J. Hematol. pmid:21207214
Hashiguchi D et al. Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts. 2011 J Biomed Mater Res A pmid:21171155
Li JY et al. Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21187391
Garcia VG et al. Treatment of experimental periodontal disease with antimicrobial photodynamic therapy in nicotine-modified rats. 2011 J. Clin. Periodontol. pmid:22092666
Hen K et al. [Osteoprotegerin--a new atherosclerosis marker]. 2011 Pol. Merkur. Lekarski pmid:22097184
Tang Y et al. Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide. 2011 J Endod pmid:22099899

Table of Content